Primary drug treatment glaucoma: Beta-blockers for versus other medications - I. Individualize initial therapy

被引:34
作者
Stamper, RL [1 ]
机构
[1] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94121 USA
关键词
beta-blockers; compliance; cost; glaucoma; side effects;
D O I
10.1016/S0039-6257(01)00286-7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
This set of viewpoints articles examines the merits of beta-blockers versus other medications as the primary drug treatment for glaucoma. Ophthalmologists must balance issues such as efficacy, compliance, cost, and side effects when deciding on the appropriate medication to prescribe. Dr. Stamper stresses the advantages of tailoring the choice of medication to the needs of the individual patient. Drs. Wigginton and Higginbotham review the benefits of beta-blockers and present some of the disadvantages of the non-beta-blocker class of medications. (Surv Ophthalmol 47:63-73, 2002. (C) 2002 by Elsevier Science Inc. All rights reserved.).
引用
收藏
页码:63 / 67
页数:5
相关论文
共 41 条
[1]   Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States [J].
Alm, A ;
Camras, CB ;
Watson, PG .
SURVEY OF OPHTHALMOLOGY, 1997, 41 :S105-S110
[2]  
ANANTHANARAYAN CR, 1993, CAN J OPHTHALMOL, V28, P80
[3]   Dorzolamide - A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension [J].
Balfour, JA ;
Wilde, MI .
DRUGS & AGING, 1997, 10 (05) :384-403
[4]  
BONOMI L, 1980, GRAEFES ARCH CLIN EX, V213, P19
[5]   Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics [J].
Brubaker, RF ;
Schoff, EO ;
Nau, CB ;
Carpenter, SP ;
Chen, KK ;
Vandenburgh, AM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 131 (01) :19-24
[6]  
Carlsen J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1087
[7]   Apparent central nervous system depression in infants after the use of topical brimonidine [J].
Carlsen, JO ;
Zabriskie, NA ;
Kwon, YH ;
Barbe, ME ;
Scott, WE .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1999, 128 (02) :255-256
[8]  
Clineschmidt CM, 1999, OPHTHALMOLOGY, V106, P17
[9]   TOPICAL TIMOLOL DECREASES PLASMA HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVEL [J].
COLEMAN, AL ;
DIEHL, DLC ;
JAMPEL, HD ;
BACHORIK, PS ;
QUIGLEY, HA .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (09) :1260-1263
[10]   Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men [J].
Dickstein, K ;
Aarsland, T .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 121 (04) :367-371